Verve Therapeutics, Inc. VERV
We take great care to ensure that the data presented and summarized in this overview for Verve Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VERV
View all-
Alphabet Inc. Mountain View, CA12.3MShares$75.8 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$40.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$30.5 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$26.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$24.6 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$24.5 Million1.5% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.43MShares$14.9 Million0.01% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY2.41MShares$14.8 Million0.08% of portfolio
-
Novo Holdings Hellerup, G72.4MShares$14.7 Million0.81% of portfolio
-
Arch Venture Management, LLC Chicago, IL2.01MShares$12.3 Million5.85% of portfolio
Latest Institutional Activity in VERV
Top Purchases
Top Sells
About VERV
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VERV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2024
|
Sekar Kathiresan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
30,000
+21.28%
|
-
|
|
Dec 04
2024
|
Sekar Kathiresan Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
30,000
-8.49%
|
-
|
|
Dec 02
2024
|
Allison Dorval Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
555
-9.35%
|
$2,775
$5.64 P/Share
|
|
Nov 29
2024
|
Allison Dorval Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+24.01%
|
-
|
|
Jun 28
2024
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+7.87%
|
$60,000
$2.87 P/Share
|
|
May 14
2024
|
Andrew D. Ashe |
BUY
Open market or private purchase
|
Direct |
76,000
+18.16%
|
$456,000
$6.26 P/Share
|
|
Apr 02
2024
|
Joan Nickerson Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
1,514
-14.88%
|
$12,112
$8.24 P/Share
|
|
Apr 01
2024
|
Joan Nickerson Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,315
+24.58%
|
-
|
|
Dec 01
2023
|
Krishna Yeshwant |
BUY
Open market or private purchase
|
Indirect |
1,800,000
+50.0%
|
$18,000,000
$10.0 P/Share
|
|
Nov 29
2023
|
Allison Dorval Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
554
-12.01%
|
$6,094
$11.45 P/Share
|
|
Nov 29
2023
|
Allison Dorval Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+28.9%
|
-
|
|
Dec 14
2022
|
Andrew Bellinger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,000
+45.78%
|
$72,000
$2.87 P/Share
|
|
Dec 01
2022
|
Andrew Bellinger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
865
-11.54%
|
$19,030
$22.95 P/Share
|
|
Nov 29
2022
|
Allison Dorval Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
554
-20.22%
|
$12,188
$22.1 P/Share
|
|
Nov 29
2022
|
Allison Dorval Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+40.63%
|
-
|
|
Nov 04
2022
|
Krishna Yeshwant |
SELL
Open market or private sale
|
Indirect |
48,583
-0.38%
|
$1,554,656
$32.0 P/Share
|
|
Nov 04
2022
|
Krishna Yeshwant |
SELL
Other acquisition or disposition
|
Indirect |
48,583
-0.79%
|
-
|
|
Nov 04
2022
|
Gv 2017 Gp, L.L.C. |
SELL
Open market or private sale
|
Indirect |
97,166
-45.37%
|
$3,109,312
$32.0 P/Share
|
|
Nov 04
2022
|
Gv 2017 Gp, L.L.C. |
SELL
Other acquisition or disposition
|
Indirect |
48,583
-0.79%
|
-
|
|
Nov 03
2022
|
Krishna Yeshwant |
SELL
Open market or private sale
|
Indirect |
49,568
-0.38%
|
$1,635,744
$33.1 P/Share
|
Last 12 Months Summary
| Bona fide gift | 30K shares |
|---|---|
| Exercise of conversion of derivative security | 35.2K shares |
| Open market or private purchase | 76K shares |
| Bona fide gift | 30K shares |
|---|---|
| Open market or private sale | 2.07K shares |